StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) stock

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$1.00+0.00 (+0.50%)

Close on Nov 17, 2026Market cap $138.97MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$138.97M
P/E ratio
–
Price to sales
–
Price to book
1.02
Dividend yield
–
Free cash flow yield
-51.05%

Fundamentals

Net income
-$80.89M
EPS, diluted
-$1.13
Free cash flow
-$70.95M
Book value per share
$1.00
Diluted shares
136M

Trading

Next earnings
Q3 FY2026, expected soon
Previous close
$1.00
Open
$0.99
Day's range
$0.96 – $1.04
Volume
438,385
Average volume (20 days)
1,078,565
Index membership
Russell 2000 (since Jun 2026)
52-week range
$0.86 – $2.66
RSI (14 days)
39.4
Volatility (1 year)
90.7%
Relative volume
0.39×

On 1 of our idea list: More cash than they're worth

Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2020, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodALXOS&P 500DifferenceALXO per yearS&P 500 per year
1 month-5.2%-4.0%−1.2 pts
3 months-49.0%-5.0%−44.0 pts
Year to date-11.1%+8.2%−19.3 pts
1 year-35.6%+11.2%−46.8 pts
3 years-89.4%+68.5%−157.9 pts-52.7%+19.0%
5 years-97.7%+67.3%−164.9 pts-52.8%+10.8%

Nine years at a glance

Fiscal years 2017 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$82.55M

Net income

-$80.89M

EPS, diluted

-$1.13

Free cash flow

-$70.95M
Reported periodTrailing twelve months

Press releases

Releases ALX Oncology filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About ALX Oncology

Pharmaceutical Preparations

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on advancing novel cancer therapies to prolong patient survival. Its clinical pipeline centers on two investigational candidates: evorpacept and ALX2004. Evorpacept is an engineered CD47-blocking fusion protein that pairs an affinity-enhanced extracellular domain of SIRPα with an inactivated Fc domain, designed to prevent hematologic toxicities while enabling the immune system to engulf cancer cells in combination with other anti-cancer treatments. The company evaluates evorpacept in clinical studies alongside targeted anti-cancer antibodies, small molecules, and checkpoint inhibitors, notably in combination with trastuzumab and chemotherapy for patients with metastatic HER2-positive breast cancer. ALX2004 is an antibody-drug conjugate targeting epidermal growth factor receptor (EGFR).

Company profile, executives and history

ALX Oncology stock: common questions

What is ALX Oncology's stock price?

ALXO closed at $1.00 on Nov 17, 2026, up 0.50% on the day. Over the past 52 weeks it traded between $0.86 and $2.66.

What is ALX Oncology's market cap?

ALX Oncology was worth $138.97M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is ALXO's P/E ratio?

ALX Oncology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.13), so it has no meaningful P/E ratio.

Does ALX Oncology pay a dividend?

No. ALX Oncology has not paid a cash dividend over the last twelve months.

When does ALX Oncology report earnings next?

ALX Oncology's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.

How has ALXO stock performed over the past year?

Including dividends, ALXO returned -35.6% over the past year, against +11.2% for the S&P 500.

How many ALXO shares are sold short?

6M shares were sold short at the latest FINRA report, 5.81% of the float, or 4.4 days of average trading volume.

Who are ALX Oncology's competitors?

Companies most similar to ALX Oncology by business, industry and size include ORIC, APVO, CTMX, PYXS, IDYA.

See a number that looks wrong?